
CGON Stock Forecast & Price Target
CGON Analyst Ratings
Bulls say
CG Oncology is well-positioned for success in the near-term with their upcoming Ph. 3 PIVOT-006 topline data and the completion of their initial HR BCG-UR NMIBC BLA in 4Q. They have a strong cash position to fund their operations through 2029, and their unique and effective approach to treating bladder cancer gives them a competitive advantage in the market. Additionally, their pipeline of clinical programs for cretostimogene has the potential to further broaden addressable market opportunities and drive future growth.
Bears say
CG Oncology is facing challenges with delay in its PIVOT-006 trial and potential competition from other players in the market, putting pressure on its stock. With the potential for additional equity financing, there is a risk for dilution and negative impact on share price. Additionally, the success of CG Oncology's drug candidate may hinge on specific factors such as durability thresholds and treatment schedule preference, and any delays in approval could negatively impact the company's stock price. Furthermore, the company may face stiff competition from other companies with greater resources.
This aggregate rating is based on analysts' research of CG oncology Inc and is not a guaranteed prediction by Public.com or investment advice.
CGON Analyst Forecast & Price Prediction
Start investing in CGON
Order type
Buy in
Order amount
Est. shares
0 shares